Division of Physiotherapy, Department of Applied Health Sciences, Hochschule für Gesundheit (University of Applied Sciences), Bochum, Germany.
Physiotherapy Department, Rehaklinik Zihlschlacht, Zihlschlacht, Thurgau, Switzerland.
Clin Rehabil. 2021 Mar;35(3):423-435. doi: 10.1177/0269215520966472. Epub 2020 Nov 11.
To examine the measurement properties of the de Morton Mobility Index (DEMMI), a performance-based clinical outcome assessment of mobility capacity, in hospital patients with Parkinson's disease.
Cross-sectional study.
Hospital patients with Parkinson's disease.
MAIN OUTCOME MEASURE(S): Structural validity and unidimensionality (Rasch analysis), construct validity, internal consistency reliability, and inter-rater reliability of the de Morton Mobility Index (scale range: 0-100 points) were established. The minimal detectable change, the 95% limits of agreement and possible floor and ceiling effects were calculated to indicate interpretability.
We analysed validity ( = 100; mean age: 70 years; 71% male) and reliability ( = 47; mean age: 71 years; 68% male) in two samples. The mean Hoehn and Yahr stage was 3.2 and the mean disease duration was 12 years in both samples. Rasch analysis indicated unidimensionality with an overall fit to the model (chi-square = 21.49, = 0.122). Seventy-three percent of hypotheses on construct validity were confirmed. Internal consistency reliability (Cronbach's alpha = 0.91) and inter-rater reliability (intraclass correlation coefficient = 0.88; 95% confidence interval: 0.80 to 0.93) were sufficient. The minimal detectable change with 90% confidence was 17.5 points and the limits of agreement were 31%. No floor or ceiling effects were observed. The mean administration time was 6.6 minutes.
This study provides evidence of unidimensionality, sufficient internal consistency reliability, inter-rater reliability, construct validity, and feasibility of the de Morton Mobility Index in hospital patients with Parkinson's disease.
German Clinical Trials Register (DRKS00004681). Registered May 6, 2013.
检验德莫顿移动指数(DEMMI)的测量性能,DEMMI 是一种基于性能的移动能力临床结局评估方法,用于评估帕金森病住院患者。
横断面研究。
帕金森病住院患者。
结构效度和单维性(Rasch 分析)、构念效度、内部一致性信度和德莫顿移动指数(量表范围:0-100 分)的评分者间信度。计算最小可检测变化、95%一致性界限以及可能的地板效应和天花板效应,以指示可解释性。
我们分析了两个样本的有效性(n=100;平均年龄:70 岁;71%为男性)和可靠性(n=47;平均年龄:71 岁;68%为男性)。两个样本的平均 Hoehn 和 Yahr 分期为 3.2,平均病程为 12 年。Rasch 分析表明具有单维性,整体符合模型(卡方=21.49,p=0.122)。73%的结构效度假设得到验证。内部一致性信度(Cronbach's alpha=0.91)和评分者间信度(组内相关系数=0.88;95%置信区间:0.80 至 0.93)充足。90%置信区间的最小可检测变化为 17.5 分,一致性界限为 31%。未观察到地板效应或天花板效应。平均管理时间为 6.6 分钟。
本研究为帕金森病住院患者的德莫顿移动指数具有单维性、充足的内部一致性信度、评分者间信度、构念效度和可行性提供了证据。
德国临床试验注册(DRKS00004681)。2013 年 5 月 6 日注册。